Rigel Pharmaceuticals (RIGL) Net Cash Flow (2010 - 2026)

Rigel Pharmaceuticals' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$16.2 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 47.51% year-over-year to -$16.2 million in Q1 2026; TTM through Mar 2026 was -$21.3 million, a 205.47% decrease from a year earlier, with the FY2025 full-year figure at -$16.1 million, down 167.23% from the prior year.
• Net Cash Flow fell to -$16.2 million in Q1 2026 per RIGL's latest filing, from -$8.0 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $15.8 million in Q1 2023 and bottomed at -$16.2 million in Q1 2026.
• The 5-year median for Net Cash Flow is $2.5 million (2022), against an average of $328117.6.
• Across the five-year window, Net Cash Flow soared 560.24% in 2024 and plunged 257.38% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at -$5.4 million in 2022, then sank by 133.55% to -$12.6 million in 2023, then surged by 140.02% to $5.1 million in 2024, then plunged by 257.38% to -$8.0 million in 2025, then sank by 103.28% to -$16.2 million in 2026.
• Per Business Quant, the three latest RIGL Net Cash Flow figures stand at -$16.2 million (Q1 2026), -$8.0 million (Q4 2025), and -$4.9 million (Q3 2025).